Premium
Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study
Author(s) -
Biemans Vince B.C.,
Woude C. Janneke,
Dijkstra Gerard,
Meulende Jong Andrea E.,
Oldenburg Bas,
Boer Nanne K.,
Löwenberg Mark,
Srivastava Nidhi,
Bodelier Alexander G.L.,
West Rachel L.,
Jansen Jeroen M.,
Vries Annemarie C.,
Haans Jeoffrey J.L.,
Jong Dirk J.,
Pierik Marie J.,
Hoentjen Frank
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1712
Subject(s) - vedolizumab , medicine , concomitant , interquartile range , ulcerative colitis , immunosuppression , inflammatory bowel disease , crohn's disease , gastroenterology , prospective cohort study , pouchitis , cohort , disease
Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow‐up period of 104 weeks (interquartile range: 103–104) in a nationwide registry. The corticosteroid‐free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty‐nine percent maintained corticosteroid‐free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow‐up regardless of concomitant immunosuppression.